Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified ginseng-schisandra decoction is a Traditional Chinese Medicine (TCM) formulation developed and utilized by the Children's Hospital of Shanghai. It is specifically indicated for the treatment of recurrent respiratory tract infections (RRTI) in pediatric patients, particularly those diagnosed with spleen deficiency syndrome. The decoction is a modification of the classic TCM formula 'Ren Shen Wu Wei Zi Tang' (Ginseng and Schisandra Decoction), which traditionally aims to tonify the qi of the lungs and spleen. The modified version typically incorporates herbs such as *Panax ginseng* (Ginseng), *Schisandra chinensis* (Schisandra), *Atractylodes macrocephala*, and *Poria cocos*. Mechanistically, the decoction acts as an immunomodulator, balancing T-lymphocyte subsets (increasing CD3+ and CD4+ levels) and enhancing the production of protective serum immunoglobulins (IgA, IgG), thereby improving the body's resistance to viral and bacterial pathogens in the respiratory tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified ginseng-schisandra decoction.